The clinical case for disease-modifying treatment
For the first time, there is a class of therapy that may slow the progression of Alzheimer's at its source, not just manage symptoms. We offer two distinct pathways. Which is right for you is a clinical question, answered by your consultant.
Two Routes to the Same Goal
Both therapies target amyloid plaques, the hallmark of Alzheimer's disease. They differ in dosing schedule, treatment duration, and how costs accrue. Your clinical profile determines which is appropriate.
Light
Fortnightly infusions over a 12-month course, with the option to continue beyond. A fixed, all-inclusive price, predictable from the outset.
Every 2 wks
Infusion frequency
Unlimited
Standard course
24
Infusions in 12 months
£49,000
12-month price
Clarity
Monthly infusions, up to 18 months maximum. Treatment stops when amyloid is cleared, confirmed by scan. Duration, and cost, are shaped by your response.
Monthly
Infusion frequency
Up to 18 months
Maximum course
Avg. 12
Typical infusions
£85,000
12-month cost
Published Phase 3
Clinical Trial Data
Both therapies have been evaluated in large, randomised, placebo-controlled trials in people with early Alzheimer's disease. The data below is drawn from published trial results. These are population-level findings; individual outcomes will vary, and your consultant will discuss what the evidence means for your specific situation.
27%
slowing of clinical decline vs placebo
Measured on the CDR-SB scale at 18 months in 1,795 participants with early Alzheimer's and confirmed amyloid pathology.
Safety profile, ARIA rates
ARIA = amyloid-related imaging abnormalities. Most cases are asymptomatic and detected on routine monitoring MRI. Symptomatic cases are managed with a treatment pause.
35%
slowing of clinical decline vs placebo (low/medium tau group)
Measured on the iADRS scale in 1,736 participants with early Alzheimer's. Results varied by tau burden, the low/medium tau subgroup showed 35% slowing; the overall population 22 to 29%.
Safety profile, ARIA rates
ARIA = amyloid-related imaging abnormalities. Most cases are asymptomatic and detected on routine monitoring MRI. Symptomatic cases are managed with a treatment pause.
A note on comparing trial data. These trials used different primary outcome measures (CDR-SB vs iADRS), different participant populations, and different dosing protocols. The efficacy figures are not directly comparable, and should not be used to choose between pathways. Your consultant will interpret what this data means for your individual profile.
What Your Consultant Will Assess
Pathway selection is a clinical decision, not a commercial one. Your consultant will assess a range of factors before recommending, or advising against, either pathway.
Amyloid burden
Confirmed by PET scan or CSF analysis. Higher amyloid burden may influence which therapy is clinically preferable.
Tau status
Tau biomarkers indicate disease stage. The Clarity Pathway trial showed stronger results in low and medium tau participants specifically.
APOE ε4 genotype
Carriers of one or two APOE ε4 alleles have higher ARIA risk on both therapies. Genotyping is mandatory before treatment starts.
Cardiovascular health
Prior microhaemorrhages, anticoagulant use, and vascular comorbidities affect eligibility and pathway risk profile.
Practical considerations
Infusion frequency, proximity to clinic, and carer availability are discussed, but do not override clinical factors in pathway selection.
Stage of diagnosis
Both pathways require early-stage MCI or mild Alzheimer's. The window for intervention narrows as disease progresses.
"The question is never which therapy sounds better; it's which therapy the patient's biology supports, and where we are in the disease timeline. Both are meaningful options; the data tells us which fits."
Consultant Neurologist, Re:Cognition Health
Transparent Costs for Both Pathways
We publish our pricing in full. The Light Pathway is a fixed all-inclusive price. The Clarity Pathway cost depends on treatment duration; use the slider to explore the range.
£49,000
Fixed · 12 months · all costs included
Covers all assessments, MRI scans, infusions, nursing, monitoring, and end-of-treatment review. The Light Pathway has no required end point; treatment can continue beyond 12 months with pricing on request.
£85,000
Estimated total · based on duration below · all costs included
Duration is clinically determined. Treatment stops when amyloid clearance is confirmed on MRI, or at 18 months at the latest.
Per-infusion costs are not directly comparable. The pathways use different dosing frequencies and protocols. The monthly equivalent (£4,083 vs £7,083) is a more meaningful comparison of ongoing treatment intensity. Payment plans and medical finance options are available; speak to our patient navigation team.
Book Your Eligibility Assessment
One consultation covers both pathwaysEverything You Need to Know
The Conversation Starts with
Your Eligibility Assessment
A single consultation with a Re:Cognition Health neurologist covers both pathways. They will review your diagnosis, biomarkers, and medical history, and advise which pathway, if either, is appropriate for you.
Re:Cognition Health is registered with the Care Quality Commission (CQC).
This page provides information about private clinical services, not named prescription medicines.